# Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

> **NCT00305864** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 118 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **DRUG:** Motexafin Gadolinium
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00305864
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-09
- **Primary completion:** 2011-02-16
- **Final completion:** 2011-03-15
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2018-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305864, "Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00305864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*